- Home
- LYRA vs NRXS Comparison
LYRA vs NRXS Comparison
Compare LYRA & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- NRXS
- Stock Information
- Founded
- LYRA 2005
- NRXS 2011
- Country
- LYRA United States
- NRXS United States
- Employees
- LYRA N/A
- NRXS N/A
- Industry
- LYRA Medical/Dental Instruments
- NRXS
- Sector
- LYRA Health Care
- NRXS
- Exchange
- LYRA Nasdaq
- NRXS Nasdaq
- Market Cap
- LYRA 15.0M
- NRXS 13.0M
- IPO Year
- LYRA 2020
- NRXS 2023
- Fundamental
- Price
- LYRA $7.95
- NRXS $2.77
- Analyst Decision
- LYRA Buy
- NRXS Strong Buy
- Analyst Count
- LYRA 2
- NRXS 1
- Target Price
- LYRA $16.00
- NRXS $7.00
- AVG Volume (30 Days)
- LYRA 91.5K
- NRXS 85.1K
- Earning Date
- LYRA 08-13-2025
- NRXS 08-08-2025
- Dividend Yield
- LYRA N/A
- NRXS N/A
- EPS Growth
- LYRA N/A
- NRXS N/A
- EPS
- LYRA N/A
- NRXS N/A
- Revenue
- LYRA $1,185,000.00
- NRXS $2,934,945.00
- Revenue This Year
- LYRA N/A
- NRXS $138,883.78
- Revenue Next Year
- LYRA $139.18
- NRXS $118.59
- P/E Ratio
- LYRA N/A
- NRXS N/A
- Revenue Growth
- LYRA N/A
- NRXS 27.52
- 52 Week Low
- LYRA $3.81
- NRXS $1.33
- 52 Week High
- LYRA $37.50
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- LYRA 41.08
- NRXS 57.38
- Support Level
- LYRA $7.77
- NRXS $2.55
- Resistance Level
- LYRA $8.67
- NRXS $2.92
- Average True Range (ATR)
- LYRA 0.45
- NRXS 0.17
- MACD
- LYRA -0.03
- NRXS 0.03
- Stochastic Oscillator
- LYRA 11.32
- NRXS 78.26
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).